Skip to main content
Scope Fluidics S.A. logo

Scope Fluidics S.A. — Investor Relations & Filings

Ticker · SCP ISIN · PLSCPFL00018 LEI · 259400EUNFX4E2BEHU15 WAR Professional, scientific and technical activities
Open in API
Filings indexed 510 across all filing types
Latest filing 2020-08-27 Director's Dealing
Country PL Poland
Listing WAR SCP

About Scope Fluidics S.A.

https://scopefluidics.com/

Scope Fluidics S.A. is a biotechnology company that develops innovative medical diagnostic solutions based on microfluidic technologies. The company's business model involves incubating projects within special-purpose vehicles (SPVs) with the goal of selling them to global strategic partners. Its primary project, developed by its subsidiary Bacteromic Sp. z o.o., is the BACTEROMIC system. This automated system provides rapid, comprehensive antimicrobial susceptibility testing (AST) to address the challenge of antibiotic resistance. Previously, the company developed the PCR|ONE system for rapid molecular diagnostics through its Curiosity Diagnostics SPV, which was acquired by Bio-Rad in 2022. The company focuses on creating fast, effective, and accessible diagnostic tools to improve healthcare outcomes.

Recent filings

Filing Released Lang Actions
Powiadomienie o transakcjach TOTAL FIZ i TTL1 Sp. z o.o.
Director's Dealing Classification · 1% confidence The document text is titled "Powiadomienie o transakcji/transakcjach, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of a transaction(s) referred to in Article 19(1) of the MAR Regulation). This regulation (MAR - Market Abuse Regulation) mandates disclosures regarding transactions conducted by persons discharging managerial responsibilities (PDMRs) or persons closely associated with them. The content details the acquisition ('Nabycie') and disposal ('Zbycie') of shares ('AKCJA') by an entity closely associated with a member of the Supervisory Board ('ROBERT PRZYTUŁA - PRZEWODNICZĄCY RADY NADZORCZEJ'). This specific type of insider transaction reporting directly corresponds to the definition of Director's Dealing (DIRS).
2020-08-27 Polish
Otrzymanie zawiadomień, o których mowa w art. 19 ust. 1 MAR - Content (PL)
Major Shareholding Notification Classification · 1% confidence The document text is very short (397 characters) and explicitly mentions receiving two notifications ('dwa zawiadomienia') under Article 19(1) of MAR Regulation concerning transactions made by persons closely associated with a management function (the Chairman of the Supervisory Board). It states that these notifications are attached to the report ('stanowią załącznik do niniejszego raportu'). This structure—a brief announcement stating that insider transaction reports (Director's Dealing) have been received and are attached—strongly suggests this is an announcement about the filing rather than the detailed filing itself. However, the core subject matter is insider transactions by directors/executives. The closest specific category is 'Director's Dealing' (DIRS). Given the brevity and the reference to attached notifications, it could potentially be RPA, but since the content is specifically about insider trades (DIRS), DIRS is the most accurate content classification, even if it's a short announcement of the filing.
2020-08-27 Polish
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na Nadzwyczajnym
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document text is titled 'Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na Nadzwyczajnym Walnym Zgromadzeniu...' which translates to 'List of shareholders holding at least 5% of the votes at the Extraordinary General Meeting...'. This content explicitly details the voting results and the percentage of votes held by major shareholders during a specific general meeting (Nadzwyczajnym Walnym Zgromadzeniu - EGM). This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document is short and contains the final results, not an announcement about a future report.
2020-08-21 Polish
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na Zwyczajnym Walnym Zgromadzeniu Spółki, które odbyło się w dniu 21 sierpnia 2020 r. - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document text is very short (203 characters) and states that the Management Board of Scope Fluidics S.A. is enclosing a list of shareholders who held at least 5% of the votes at the Ordinary General Meeting (Zwyczajnym Walnym Zgromadzeniu) held on August 21, 2020. This content relates directly to the results or participants of a shareholder meeting. Since it is an announcement providing specific voting/shareholder data from a general meeting, it aligns best with the Declaration of Voting Results & Voting Rights Announcements (DVA). It is not a full report, presentation, or transcript.
2020-08-21 Polish
Podpisanie umowy, której celem jest wykonanie oceny skuteczności klinicznej systemu PCR|ONE panel SARS-CoV-2 w ramach w procedury FDA Emergency Use Authorisation, umożliwiającej dopuszczenie produk...
Regulatory Filings Classification · 1% confidence The document text is a formal announcement by the Management Board ("Zarząd") of Scope Fluidics S.A. regarding the signing of an agreement for clinical effectiveness evaluation of their SARS-CoV-2 PCR test panel under the FDA Emergency Use Authorization (EUA) procedure. This concerns a specific business development, regulatory pathway pursuit (FDA EUA), and potential market impact. It is not a full financial report (10-K, IR), an earnings release (ER), a dividend notice (DIV), or a general regulatory filing (RNS). It details a significant business transaction/development related to product approval and market access, which aligns best with an announcement concerning major business activities or regulatory steps that impact the company's operations and value, but does not fit perfectly into M&A (TAR) or Financing (CAP). Given the focus on a specific legal/regulatory agreement impacting product commercialization, it is most closely related to Legal Proceedings/Regulatory Matters, but since it is a proactive step towards market entry rather than a lawsuit, and it is a significant operational update, it falls under the general category of important corporate news. Since there is no specific code for 'Regulatory Approval Pursuit' or 'Major Contract Signing', and it is a detailed update on a specific business/regulatory matter, it is best classified as a Regulatory Filing (RNS) as a catch-all for significant, non-standard announcements, or potentially LTR if viewed as a regulatory matter, but RNS is safer for general significant announcements not covered elsewhere. However, upon review, this is a specific announcement about a contract to pursue FDA authorization, which is a critical business development. Since it is not a standard financial report, dividend, or management change, and it details a specific agreement, RNS (Regulatory Filings/Miscellaneous) is the most appropriate fallback if a more specific code like 'Business Development' is missing. Given the context of FDA procedures, it is a significant regulatory/operational update. I will classify it as RNS as it is a specific, non-standard corporate announcement.
2020-08-17 Polish
Otrzymanie przez Curiosity Diagnostics certyfikatu ISO 13485:2016 - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a short announcement (899 characters) from the Management Board ('Zarząd') of Scope Fluidics S.A. regarding its subsidiary receiving an ISO 13485:2016 certificate from the Polish Centre for Testing and Certification (PCBC). This announcement details a specific operational achievement and compliance milestone, but it is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). It is a general regulatory or operational update. Since it doesn't fit the specific categories like DIRS, DIV, or CAP, and it is a formal announcement of a compliance achievement, it best fits the general 'Regulatory Filings' category as a miscellaneous, non-standard announcement, or potentially 'RPA' if it were announcing the publication of a larger document, but here it is the news itself. Given the options, 'RNS' (Regulatory Filings / miscellaneous announcements) is the most appropriate fallback for this type of operational compliance news that isn't covered by the other specific codes.
2020-07-28 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.